Leerink Partners Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock

Key Points

• Leerink Partners raised Replimune’s price target from $19 to $31 while maintaining an “outperform” rating, implying approximately 81% upside from the reported $17.14 share price.
• Replimune shares rose 6.8% after the company reported a quarterly loss of $0.54 per share, narrower than the $0.78 consensus estimate. Analysts’ average rating is “Moderate Buy,” with an average price target of $14.33.
• The company’s launch outlook is supported by early TUDRIQEV prescribing activity and $307.8 million in cash, though Replimune remains unprofitable and dependent on successful commercialization and future reimbursement support.

Replimune Group (NASDAQ:REPL - Get Free Report) had its price objective boosted by analysts at Leerink Partners from $19.00 to $31.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Leerink Partners's price objective points to a potential upside of 80.81% from the company's current price.

Other equities analysts have also recently issued research reports about the company. Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 26th. Wolfe Research upgraded shares of Replimune Group to an "outperform" rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $14.33.

Replimune Group Stock Up 6.8%

NASDAQ:REPL traded up $1.08 during mid-day trading on Thursday, hitting $17.14. The company had a trading volume of 3,602,239 shares, compared to its average volume of 4,325,783. The business has a fifty day simple moving average of $13.46 and a 200-day simple moving average of $9.25. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.46 and a beta of 0.93. Replimune Group has a 1 year low of $1.50 and a 1 year high of $17.57. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.24. Equities analysts forecast that Replimune Group will post -2.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the sale, the chief executive officer directly owned 708,151 shares in the company, valued at $9,184,718.47. The trade was a 5.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. The trade was a 4.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 in the last quarter. Company insiders own 5.40% of the company's stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Replimune Group in the 2nd quarter worth approximately $99,171,000. Opaleye Management Inc. acquired a new position in Replimune Group during the 2nd quarter valued at approximately $15,332,000. EcoR1 Capital LLC bought a new position in Replimune Group during the 1st quarter worth $7,650,000. ADAR1 Capital Management LLC bought a new position in Replimune Group during the 2nd quarter worth $7,260,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Replimune Group in the second quarter worth $5,485,000. Institutional investors own 92.53% of the company's stock.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Replimune reported a fiscal second-quarter loss of $0.54 per share, beating the consensus estimate for a $0.78 loss. The result may have improved sentiment despite the company remaining unprofitable. Replimune earnings results
• Positive Sentiment: Early TUDRIQEV adoption is encouraging: More than 15 institutions prescribed TUDRIQEV within 20 business days, after the therapy was first delivered to patients on October 6. The initial prescribing activity supports expectations for a faster commercial ramp. Replimune corporate update
• Positive Sentiment: Solid liquidity supports the launch: Replimune ended the quarter with $307.8 million in cash, providing funding for commercialization and clinical development while management works to expand TUDRIQEV’s market presence. Replimune long-term investor takeaways
• Neutral Sentiment: Permanent reimbursement code remains a future catalyst: Management anticipates receiving a permanent J-code for TUDRIQEV by April 2027. The code could simplify reimbursement and support adoption, but it has not yet been granted. Replimune J-code update
• Negative Sentiment: Replimune continues to generate losses: The earnings beat reflects lower-than-expected losses rather than profitability, leaving the company dependent on successful TUDRIQEV commercialization and continued access to capital.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.